Abstract:Autophagy inhibition could hinder the underlying protective mechanisms in the course of tumor treatment. The advances in autophagy inhibition have driven focus on the functionalized nanoplatforms by combining the current treatment paradigms with complementary autophagy inhibition for enhanced efficacy. Furthermore, Ca2+ overload is also a promising adjuvant target for the tumor treatment by augmenting mitochondrial damage. In this view, complementary mitochondrial Ca2+ overload and autophagy inhibition were first demonstrated as a novel strategy suitable for homing in on the shortage of photodynamic therapy (PDT). We constructed biodegradable tumor-targeted inorganic/organic hybrid nanocomposites (DPGC/OI) synchronously encapsulating IR780 and Obatoclax by biomineralization of the nanofilm method, which consists of pH-triggered calcium phosphate (CP), long circulation phospholipid block copolymers 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)-poly(ethylene glycol) (PEG)2000-glucose (DPG). In the presence of the hydrophilic PEG chain and glucose transporter 1 (Glut-1) ligands, DPGC would become an effectively tumor-oriented nanoplatform. Subsequently, IR780 as an outstanding photosensitizer could produce increased amounts of toxic reactive oxygen species (ROS) after laser irradiation. Calcium phosphate (CP) as the Ca2+ nanogenerator could generate Ca2+ at low pH to induce mitochondrial Ca2+ overload. The dysfunction of mitochondria could enhance increased amounts of ROS. Based on the premise that autophagy would degrade dysfunctional organelles to sustain metabolism and homeostasis, which might participate in resistance to PDT, Obatoclax as an autophagy inhibitor would hinder the protective mechanism from cancer cells with negligible toxicity. Such an enhanced PDT via mitochondrial Ca2+ overload and autophagy inhibition could be realized by DPGC/OI.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsami.1c11583.Scanning electron microscope (SEM) imaging of CP, DPGC, and DPGC/OI (Figure S1); size distribution of DPGC/OI in serum (Figure S2); FT-IR of CP, DPGC, and DSPE-PEG-glucose (Figure S3); TEM images of DPGC/OI after incubation for 0.5 h in (Figure S4A) pH 5.2 and (Figure S4B) pH 7.4, respectively; temperature curves of IR780 + NIR and DPGC/OI + NIR after 1 min laser irradiation (Figure S5); release profiles of IR780 and Obatoclax from DPGC/OI (Figure S6A,B); CLSM images of 4T1 cancer cells treated with DPGC/I at different time points (Figure S7); ROS generation in 4T1 cells after treatment with IR780 and CP/I upon laser exposure after 48 h (Figure S8); matching histogram analysis of cleaved Caspase-3 (Figure S9); live and dead images of 4T1 cells treated with different treatments for 48 h (Figure S10); histogram Individual blood analysis of mice at 15 days after different treatments (Figure S11); tumors dissected from mice after 15 days with H&E and TUNEL staining (Figure S12); H&E staining of tissues collected from mice after 15 days of different treatments, scale bar = 200 μm (Figure S13); relative volume changes (Figure S14A) and mice body weight changes in different groups (Figure S14B), data are mean ± SD, n = 5; *P < 0.05, **P < 0.01, and ***P < 0.001 vs control; photographs of tumors ex vivo in different treatment groups within 15 days (Figure S14C) (PDF)This article has not yet been cited by other publications.

Reversing Multidrug Resistance by Inducing Mitochondrial Dysfunction for Enhanced Chemo-Photodynamic Therapy in Tumor

Mitochondria Targeted Nanoparticles Potentiate Tumor Chemo-Phototherapy by Toxic Oxidative Stress Mediated Oxeiptosis

Mitochondria-targeted nanoplatforms for enhanced photodynamic therapy against hypoxia tumor

Boosting the Photodynamic Therapy Efficiency with a Mitochondria-Targeted Nanophotosensitizer

Self-Monitoring the Endo-Lysosomal Escape and Near-Infrared-Activated Mitophagy To Guide Synergistic Type-I Photodynamic and Photothermal Therapy

Liposome-Based Nanoencapsulation of a Mitochondria-Stapling Photosensitizer for Efficient Photodynamic Therapy

Efficient Photodynamic Therapy Nanocarriers with Oxygen Saving and Smart Releasing–Translocating Properties

A Ph-Activatable Nanoparticle for Dual-Stage Precisely Mitochondria-Targeted Photodynamic Anticancer Therapy.

Colloidally Stabilized DSPE-PEG-Glucose/Calcium Phosphate Hybrid Nanocomposites for Enhanced Photodynamic Cancer Therapy via Complementary Mitochondrial Ca 2+ Overload and Autophagy Inhibition

A cyclic nano-reactor achieving enhanced photodynamic tumor therapy by reversing multiple resistances

"Transforming enemy into friend" strategy-based stimuli responsive dual-drug liposomes for synergistic chemo-photodynamic therapy

Mitochondria-Responsive Drug Release along with Heat Shock Mediated by Multifunctional Glycolipid Micelles for Precise Cancer Chemo-Phototherapy.

Photodynamic Therapy-Accelerated Hypoxia-Responsive Prodrug Release for Synergistic Photo-Chemotherapy of Melanoma Cancer based on Noncovalent Interactions

Supramolecular micelles as multifunctional theranostic agents for synergistic photodynamic therapy and hypoxia-activated chemotherapy

Overcoming Hypoxia by Multistage Nanoparticle Delivery System to Inhibit Mitochondrial Respiration for Photodynamic Therapy

Mitochondria-targeting polydopamine-coated nanodrugs for effective photothermal- and chemo-synergistic therapies against lung cancer

Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based “combo” nanoagent together with PD-L1 blockade in reversing multidrug resistance

Organelle‐Specific Anchored Delivery System Stretching a Reversal of Tumor Hypoxia Microenvironment to a Combinational Chemo‐Photothermal Therapy

Immune/Hypoxic Tumor Microenvironment Regulation-Enhanced Photodynamic Treatment Realized by pH-Responsive Phase Transition-Targeting Nanobubbles

Stereocomplex Crystallized Nanomedical System for Enhanced Type I PDT and Synergistic Chemo-Phototherapy

Enhanced porphyrin-based fluorescence imaging-guided photodynamic/photothermal synergistic cancer therapy by mitochondrial targeting